$5 million grant to test Alzheimer’s treatment

Israel’s ImmunoBrain Checkpoint (see here previously) has been awarded a grant of $5 million over 3 years to support human clinical trials of IBC-Ab002, for the treatment of Alzheimer’s disease. Development was based on Weizmann Institute immune system studies.

https://www.weizmann-usa.org/news-media/in-the-news/immunobrain-checkpoint-awarded-5-million-us-nia-grant-for-phase-1b-alzheimer-s-disease/

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published.